Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance

Breast Cancer Research and Treatment

Volumn 124, Issue 3, 2010, Pages 733-743

  Zhao, Xinmin ^a   Xu, Xiaofeng ^a,b   Guo, Lin ^a,b   Ragaz, Joseph ^c,d   Guo, Haiyi ^a   Wu, Jiong ^a,b   Shao, Zhimin ^a,b   Zhu, Ji ^a,b   Guo, Xiaomao ^a,b   Chen, Jiayi ^a,b   Zhu, Beiling ^a,b   Wang, Zhonghua ^a   Hu, Xichun ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Advanced breast cancer; Bone metastases; N telopeptide of type I collagen; VEGF; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NAVELBINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAXANE DERIVATIVE; VASCULOTROPIN; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG WITHDRAWAL; FEVER; HEMATURIA; HUMAN; LOW DRUG DOSE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; METRONOMIC CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHINA; COLLAGEN TYPE I; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUCIN-1; PEPTIDES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649332137     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1183-6     Document Type: Article

References (41)

1. A Osborne 2002 Zoledronic acid Clin J Oncol Nurs 6 365 366 10.1188/02.CJON.365-366 12434471
2. TA Guise 2008 Antitumor effects of bisphosphonates: promising preclinical evidence Cancer Treat Rev 34 S19 S24 10.1016/j.ctrv.2008.03.006 18486348
3. A Lipton 2008 Emerging role of bisphosphonates in the clinic -antitumor activity and prevention of metastasis to bone Cancer Treat Rev 34 S25 S30 10.1016/j.ctrv.2008.03.008 18486347
4. Ottewell PD, Lefley DV, Coleman RE, Holen I (2008) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer. Presented at 31st annual San Antonio breast cancer symposium (SABCS), San Antonio, TX, USA, Dec 10-14, 2008 (abstr 2151)
5. Solomayer EF, Gebauer G, Hirnle P, et al (2008) Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at 31st annual San Antonio breast cancer symposium (SABCS), San Antonio, TX, USA, Dec 10-14, 2008 (abstr 2048)
6. E Giraudo M Inoue D Hanahan 2004 An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 114 623 633 15343380
7. M Gnant B Mlineritsch G Luschin-Ebengreuth, et al. 2007 Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol 25 820 828 10.1200/JCO.2005.02.7102 17159195 (Pubitemid 350002882)
8. M Gnant B Mlineritsch W Schippinger, et al. 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 679 691 10.1056/NEJMoa0806285 19213681
9. NJ Bundred ID Campbell N Davidson, et al. 2008 Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results Cancer 112 1001 1010 10.1002/cncr.23259 18205185 (Pubitemid 351304583)
10. RE Coleman 2009 Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 45 1909 1915 10.1016/j.ejca.2009.04.022 19447606
11. Chlebowski RT, Chen Z, Cauley JA et al (2009) Oral bisphosphonate and breast cancer: prospective results from the women's health initiative (WHI). Presented at 32nd annual San Antonio breast cancer symposium (SABCS), San Antonio, TX, USA, Dec 9-13, 2009 (abstr 21)
12. Rennert G, Pinchev M, Rennert HS (2009) Use of bisphosphonates and risk of postmenopausal breast cancer. Presented at 32nd annual San Antonio breast cancer symposium (SABCS), San Antonio, TX, USA, Dec 9-13, 2009 (abstr 27)
13. B Vincenzi D Santini G Dicuonzo, et al. 2005 Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients J Interferon Cytokine Res 25 144 151 10.1089/jir.2005.25.144 15767788 (Pubitemid 40354834)
14. G Gasparini M Toi M Gion, et al. 1997 Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma J Natl Cancer Inst 89 139 147 10.1093/jnci/89.2.139 8998183
15. JE Brown RJ Cook P Major, et al. 2005 Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 59 69 10.1093/jnci/dji002 15632381
16. RE Coleman P Major A Lipton, et al. 2005 Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid J Clin Oncol 23 4925 4935 10.1200/JCO.2005.06.091 15983391 (Pubitemid 46223998)
17. EC Coveney JG Geraghty F Sherry EW McDermott JJ Fennelly NJ O'Higgins MJ Duffy 1995 The clinical value of CEA and CA 15-3 in breast cancer management Int J Biol Markers 10 35 41 7629425
18. B Massidda MT Ionta MR Foddi L Mascia F Bruder MB Aloi C Meleddu MN Giannoni 1996 Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma Anticancer Res 16 2221 2223 8694547
19. DM Black PD Delmas R Eastell, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
20. DL Hershman DJ McMahon KD Crew, et al. 2008 Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer J Clin Oncol 26 4739 4745 10.1200/JCO.2008.16.4707 18711172
21. D Santini B Vincenzi S Galluzzo, et al. 2007 Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients Clin Cancer Res 13 4482 4486 10.1158/1078-0432.CCR-07-0551 17671133 (Pubitemid 47219717)
22. A Bottini D Generali MP Brizzi, et al. 2006 Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients J Clin Oncol 24 3623 3628 10.1200/JCO.2005.04.5773 16877730 (Pubitemid 46630536)
23. AD Seidman D Berry C Cirrincione, et al. 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Conventional arm protocol 9840 J Clin Oncol 26 1642 1649 10.1200/JCO.2007.11.6699 18375893
24. D Santini B Vincenzi G Dicuonzo, et al. 2003 Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients Clin Cancer Res 9 2893 2897 12912933
25. F Daubiné C Le Gall J Gasser J Green P Clézardin 2007 Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis J Natl Cancer Inst 99 322 330 10.1093/jnci/djk054 17312309 (Pubitemid 47073494)
26. RM Bremnes C Camps R Sirera 2006 Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood Lung Cancer 51 143 158 10.1016/j.lungcan.2005.09.005 16360975 (Pubitemid 43144358)
27. A Lipton L Costa SM Ali LM Demers 2001 Bone markers in the management of metastatic bone disease Cancer Treat Rev 27 181 185 10.1053/ctrv.2000.0212 11417969 (Pubitemid 32452019)
28. G Ferretti A Fabi P Carlini, et al. 2005 Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients Oncology 69 35 43 10.1159/000087286 16088233 (Pubitemid 41207056)
29. D Santini B Vincenzi RA Hannon, et al. 2006 Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours Oncol Rep 15 1351 1357 16596210
30. IJ Diel EF Solomayer SD Costa, et al. 1998 Reduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 357 363 10.1056/NEJM199808063390601 9691101 (Pubitemid 28363797)
31. TE Delea C Taneja O Sofrygin S Kaura M Gnant 2010 Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer Clin Breast Cancer 10 267 274 10.3816/CBC.2010.n.034 20705558
32. PV Dickson JB Hamner TL Sims, et al. 2007 Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clin Cancer Res 13 3942 3950 10.1158/1078-0432.CCR-07-0278 17606728 (Pubitemid 47037602)
33. M Sabatino S Kim-Schulze MC Panelli, et al. 2009 Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy J Clin Oncol 27 2645 2652 10.1200/JCO.2008.19.1106 19364969
34. B Vincenzi D Santini A Russo, et al. 2007 Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan Pharmacogenomics 8 319 327 10.2217/14622416.8.4.319 17391070 (Pubitemid 46585495)
35. F Tas D Duranyildiz H Oguz H Camlica V Yasasever E Topuz 2008 Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases Med Oncol 25 346 349 10.1007/s12032-008-9043-5 18204821
36. E Amir M Trinkaus CE Simmons G Dranitsaris MJ Clemons 2009 Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer J Clin Pathol 62 474 476 10.1136/jcp.2008.062505 19398598
37. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 15175435 (Pubitemid 38702844)
38. D Santini F Martini ME Fratto, et al. 2009 In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients Cancer Immunol Immunother 58 31 38 10.1007/s00262-008-0521-6 18458903
39. AJ Roelofs M Jauhiainen H Mönkkönen, et al. 2009 Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP Br J Haematol 144 245 250 10.1111/j.1365-2141.2008.07435.x 19016713
40. Hu X, Zhao X, Xu X, et al (2009) Antitumor and bone-preserving effects of metronomic weekly use of zoledronic acid as compared to conventional zoledronic acid given every-four-weeks for breast cancer with bone metastases. Presented at 2009 breast cancer symposium (ASCOBCS), San Francisco, CA, USA, Oct 8-10, 2009 (abstr 217)
41. A Okines D Cunningham 2009 Current perspective: bevacizumab in colorectal cancer-a time for reappraisal? Eur J Cancer 45 2452 2461 10.1016/j.ejca.2009. 06.028 19643598